A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1